S. Karatapanis

发表

Ultrasonographic Prevalence and Factors Predicting Left Ventricular Diastolic Dysfunction in Patients with Liver Cirrhosis: Is There a Correlation between the Grade of Diastolic Dysfunction and the Grade of Liver Disease?

V. Papastergiou, L. Skorda, P. Lisgos, 2012, TheScientificWorldJournal.

Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

V. Papastergiou, S. Karatapanis, 2015, World journal of clinical cases.

A case of a large ovarian tumour

S. Karatapanis, A. Kotis, Vasilios Papamargaritis, 2011, BMJ Case Reports.

Factors that May Affect Treatment Outcome of Triple Helicobacter pylori Eradication Therapy with Omeprazole, Amoxicillin, and Clarithromycin

S. Raptis, A. Mentis, S. Ladas, 2004, Digestive Diseases and Sciences.

Effectiveness of two quadruple, tetracycline‐ or clarithromycin‐containing, second‐line, Helicobacter pylori eradication therapies

A. Mentis, S. Ladas, K. Triantafyllou, 2002, Alimentary pharmacology & therapeutics.

Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study.

G. Touloumi, G. Kitis, G. Dalekos, 2016, Hippokratia.

Treatment of chronic hepatitis C with direct‐acting antivirals in patients with β‐thalassaemia major and advanced liver disease

I. Goulis, J. Koskinas, Konstantinos Maragkos, 2017, British journal of haematology.

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)

T. Asselah, T. Pilot‐Matias, S. Pol, 2019, Health science reports.

Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis due to HBeAg negative chronic HBV infection

C. Triantos, S. Manolakopoulos, J. Vlachogiannakos, 2004, American Journal of Gastroenterology.

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?

D. Dimitroulopoulos, V. Papastergiou, L. Skorda, 2012, Journal of medical virology.

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

G. Bakalos, K. Mimidis, E. Zintzaras, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Hepatitis C Virus Genotype 5: Prospective Evaluation of Peginterferon/Ribavirin Treatment Efficacy and Predictive Value of On-treatment Virological Responses for Sustained Virological Response

V. Papastergiou, S. Karatapanis, P. Lisgos, 2014, Journal of clinical gastroenterology.

Treatment of Helicobacter pylori infection: Past, present and future.

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2014, World journal of gastrointestinal pathophysiology.

Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2015, Expert opinion on pharmacotherapy.

Lamivudine monotherapy in HBeAg‐negative chronic hepatitis B: prediction of response‐breakthrough and long‐term clinical outcome

G. Sourvinos, G. Touloumi, C. Triantos, 2006, Alimentary pharmacology & therapeutics.

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis

E. Cholongitas, G. Papatheodoridis, A. Karlaftis, 2015, Annals of gastroenterology.

Higher rates of chronic hepatitis B infection and low vaccination-induced protection rates among parturients escaping HBsAg prenatal testing in Greece: a 2-year prospective study

S. Marinopoulos, A. Antsaklis, V. Papastergiou, 2012, European journal of gastroenterology & hepatology.

Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction

J. Kountouras, K. Mimidis, D. Dimitroulopoulos, 2010, European journal of gastroenterology & hepatology.

Hepatitis C virus genotyping in Greece: Unexpected high prevalence of genotype 5a in a Greek island

I. Goulis, V. Papastergiou, L. Skorda, 2012, Journal of medical virology.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study

V. Papastergiou, P. Lisgos, S. Karatapanis, 2013, European journal of gastroenterology & hepatology.

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Christos G Gogos, G. Touloumi, G. Papatheodoridis, 2014, Hippokratia.

Elemental mercury mixed with alcohol injected intravenously as a suicide attempt

S. Karatapanis, A. Kotis, Fotini Lamprianou, 2015, BMJ Case Reports.

Expression of Smad4 and TGF-β2 in Colorectal Carcinoma

D. Anagnostakis, E. Kakouri, E. Kakouri, 2006 .

Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial

F. Laoudi, E. Xirouchakis, V. Papastergiou, 2013, Journal of clinical gastroenterology.

Evaluation of a Four‐drug, Three‐antibiotic, Nonbismuth–containing “Concomitant” Therapy as First‐line Helicobacter pylori Eradication Regimen in Greece

E. Xirouchakis, V. Papastergiou, L. Skorda, 2012, Helicobacter.

Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2014, World journal of gastroenterology.

Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2012, Gastroenterology research and practice.

Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer

S. Marinopoulos, L. Skorda, S. Karatapanis, 2008, Medical oncology.

Helicobacter pylori and colorectal neoplasia: Is there a causal link?

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2016, World journal of gastroenterology.

Ultrasound and CT imaging assessment of renal angiomyolipoma

S. Karatapanis, A. Kotis, F. Lisgos, 2010, BMJ Case Reports.

Can 24‐h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis?

E. Cholongitas, V. Papastergiou, S. Karatapanis, 2012, Liver international (Print).

Current options for the treatment of Helicobacter pylori

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2013, Expert opinion on pharmacotherapy.

Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial

A. Mentis, E. Xirouchakis, V. Papastergiou, 2017, Annals of gastroenterology.

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection

V. Papastergiou, L. Skorda, S. Karatapanis, 2009 .

Current and future insights in H. pylori eradication regimens: the need of tailoring therapy.

V. Papastergiou, S. Karatapanis, S. Georgopoulos, 2014, Current pharmaceutical design.

Letter: response‐guided treatment of hepatitis C virus genotype 5 may be feasible

V. Papastergiou, S. Karatapanis, 2014, Alimentary pharmacology & therapeutics.

Expression of Smad4 and TGF-beta2 in colorectal carcinoma.

D. Anagnostakis, E. Kakouri, S. Karatapanis, 2006, Anticancer research.

HERACLIS‐HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg‐positive patients

E. Cholongitas, K. Mimidis, D. Christodoulou, 2023, Liver international : official journal of the International Association for the Study of the Liver.